Alto Neuroscience Inc ANRO

$25.37 -1.14 (-4.30%)

Valuation

Market cap
1,017,616,000
Revenue TTM
$0
Net income TTM
$-63,240,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.05

Trading

Volume
522,500
Avg volume
652,806
Day's range
$24.40 – $26.48
Shares out
40,111,000
Stochastic %K
11%
Beta
1.42
Analysts
Strong Buy
Price target
$38.22

Price

Company profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat pa...

Show more

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 200 0412
Website
https://www.altoneuroscience.com
Address
650 Castro Street, Suite 450, Mountain View, United States

Latest news

Stocktwits

AXLFI_HQ Nov 19, 2:08 PM
The most recent Momentum signal on $ANRO triggered on 2026-11-18. The expected return for the selected horizon is +92.94% with a historical profit probability of +48.39%. Learn more: https://axlfi.com/factors/stock/ANRO/momentum/daily?pass=eyJrIjoibGluayIsImUiOjE3OTUyNzAxMjl9.ojrNtxPZlEUkOmpX1yjoTA
0 replies
Makingmillions192 Nov 16, 8:38 PM
$LEXX Alto Neuroscience ($ANRO) — Clinical-Stage Biotech Re-Rating Armistice built a substantial stake in Alto Neuroscience (holding ~864k shares via 13F/13G disclosures) while the stock was heavily discounted at ~$4.65—nearly identical to $LEXX's current ~$4.44 level. Bullet The Catalyst & Move: Following clinical pipeline progress and positive Phase 2 psychiatry/biomarker momentum, the stock staged a +535% surge, climbing into the high-$20S as institutional buyers re-rated its clinical platform.
0 replies
vmst1 Nov 13, 1:15 AM
$ANRO Just posted below my two posts from April 2026. The mystery of this stock is hard to solve. By the end of 2027, There will be more concrete info about the real potential of ALTO 207.
0 replies
vmst1 Nov 13, 1:09 AM 0 replies
vmst1 Nov 13, 1:09 AM 0 replies
stockpicker63 Nov 11, 3:17 PM
$ANRO chart of the week now more than 20% profit!
0 replies
BenTheDo Nov 10, 3:11 PM
$ANRO seems like a good short going into earnings
0 replies
GTA_Terminal Nov 8, 11:45 PM
Unusual options activity in $ANRO. Money on both sides, which usually means traders expect a move but don't agree on the direction. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ANRO&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ANRO Read the full article for the full details: https://globaltradersacademy.com/articles/anro-technical-levels-options-flow-mixed-between-22-86-and-25-45?utm_source=stocktwits&utm_medium=social
0 replies